Nucryst, Smith & Nephew deal

Smith & Nephew will acquire substantially all of Nucryst's assets for $21 million in cash, plus the value of working capital. The sale includes Nucryst's Silcryst nanocrystalline silver coating technology, for which Smith & Nephew has worldwide rights for use in wound care products. Smith & Nephew also will receive Nucryst's NPI 32101, a nanocrystalline silver powder in preclinical testing for infectious diseases. The sale, which has been approved by Nucryst's board, is subject to the approval of Nucryst shareholders. KPMG Corporate Finance Inc. advised Nucryst. ...